Most importantly, the future of PC treatment will likely include 177Lu-PSMA therapy, as it has demonstrated high response rates, low toxicity, and improved quality of life for men diagnosed with metastatic CRPC, despite prior treatment with docetaxel, cabazitaxel, or a second AR pathway antagonist, abiraterone, after enzalutamide (38,39). The gene discussed is FOLH1; the disease is pachyonychia congenita.